------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->
Bolder BioTechnology Receives Funding From the National Cancer
Institute to Evaluate Efficacy of a Second Generation Interferon
Gamma Protein for Treating Ovarian Cancer
WHEAT RIDGE, Colo., Aug. 12 -- Bolder BioTechnology, Inc.
today announced that it has been awarded a $121,844 Phase I Small
Business Innovation Research (SBIR) grant from the National Cancer
Institute of The National Institutes of Health. The grant provides
funds to evaluate effectiveness of the company's proprietary long
acting gamma interferon analog for the treatment of ovarian cancer
in animal models.
The SBIR program is a peer-reviewed grant program that provides
research support to small businesses to discover and develop
innovative biomedical products for the treatment of serious unmet
medical needs. Companies that successfully meet the goals of the
Phase I grant are eligible to apply for an additional $750,000 in
Phase II grant support to continue their product development efforts.
Bolder BioTechnology, Inc. uses advanced protein engineering
technologies to create proprietary, long-acting human protein
pharmaceuticals for the treatment of hematopoietic and endocrine
disorders, cancer and infectious diseases. For additional
information about Bolder BioTechnology, Inc., please visit our web
site at www.bolderbio.com.
Statements contained herein that are not historical facts are
forward-looking statements that are subject to a variety of risks and
uncertainties. There are a number of important factors that could
cause
actual results to differ materially from those expressed in any
forward-
looking statements made by the Company. These factors include, but
are not
limited to: (1) the Company's ability to successfully complete
product
research and development, including pre-clinical and clinical
studies, and
commercialization; (2) the Company's ability to obtain required
government
approvals; (3) the Company's ability to attract and/or maintain
manufacturing,
sales, distribution and marketing partners; and (4) the Company's
ability to
develop and commercialize its products before its competitors.
SOURCE Bolder BioTechnology, Inc.
Web Site: www.bolderbio.com
http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/";>Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/";>Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/";>Arizona High Tech</a>
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
